Abstract Reason 4 O O
Vaccines Reason 4 O O
play Reason 4 O O
a Reason 4 O O
critical Reason 4 O O
role Reason 4 O O
in Reason 4 O O
combating Reason 4 O O
the Reason 4 O O
COVID-19 Reason 4 O O
pandemic. Reason 4 O O
Future Reason 5 O O
control Reason 5 O O
of Reason 5 O O
the Reason 5 O O
pandemic Reason 5 O O
requires Reason 5 O O
improved Reason 5 O O
vaccines Reason 5 O O
with Reason 5 O O
high Reason 5 O O
efficacy Reason 5 O O
against Reason 5 O O
newly Reason 5 O O
emerging Reason 5 O O
SARS-CoV-2 Reason 5 O O
variants Reason 5 O O
and Reason 5 O O
the Reason 5 O O
ability Reason 5 O O
to Reason 5 O O
reduce Reason 5 O O
virus Reason 5 O O
transmission. Reason 5 O O
Here Reason 4 O O
we Reason 4 O O
compare Reason 4 O O
immune Reason 4 O O
responses Reason 4 O O
and Reason 4 O O
preclinical Reason 4 O O
efficacy Reason 4 O O
of Reason 4 O O
the Reason 4 O O
mRNA Reason 4 O O
vaccine Reason 4 O O
BNT162b2, Reason 4 O O
the Reason 4 O O
adenovirus-vectored Reason 4 O O
spike Reason 4 O O
vaccine Reason 4 O O
Ad2-spike Reason 4 O O
and Reason 4 O O
the Reason 4 O O
live-attenuated Reason 4 O O
virus Reason 4 O O
vaccine Reason 4 O O
candidate Reason 4 O O
sCPD9 Reason 4 O O
in Reason 4 O O
Syrian Reason 4 O O
hamsters, Reason 4 O O
using Reason 4 O O
both Reason 4 O O
homogeneous Reason 4 O O
and Reason 4 O O
heterologous Reason 4 O O
vaccination Reason 4 O O
regimens. Reason 4 O O
Comparative Reason 4 O O
vaccine Reason 4 O O
efficacy Reason 4 O O
was Reason 4 O O
assessed Reason 4 O O
by Reason 4 O O
employing Reason 4 O O
readouts Reason 4 O O
from Reason 4 O O
virus Reason 4 O O
titrations Reason 4 O O
to Reason 4 O O
single-cell Reason 4 O O
RNA Reason 4 O O
sequencing. Reason 4 O O
Our Reason 4 O O
results Reason 4 O O
show Reason 4 O O
that Reason 4 O O
sCPD9 Reason 4 O O
vaccination Reason 4 O O
elicited Reason 4 O O
the Reason 4 O O
most Reason 4 O O
robust Reason 4 O O
immunity, Reason 4 O O
including Reason 4 O O
rapid Reason 4 O O
viral Reason 4 O O
clearance, Reason 4 O O
reduced Reason 4 O O
tissue Reason 4 O O
damage, Reason 4 O O
fast Reason 4 O O
differentiation Reason 4 O O
of Reason 4 O O
pre-plasmablasts, Reason 4 O O
strong Reason 4 O O
systemic Reason 4 O O
and Reason 4 O O
mucosal Reason 4 O O
humoral Reason 4 O O
responses, Reason 4 O O
and Reason 4 O O
rapid Reason 4 O O
recall Reason 4 O O
of Reason 4 O O
memory Reason 4 O O
T Reason 4 O O
cells Reason 4 O O
from Reason 4 O O
lung Reason 4 O O
tissue Reason 4 O O
after Reason 4 O O
challenge Reason 4 O O
with Reason 4 O O
heterologous Reason 4 O O
SARS-CoV-2. Reason 4 O O
Overall, Reason 4 O O
our Reason 4 O O
results Reason 4 O O
demonstrate Reason 4 O O
that Reason 4 O O
live-attenuated Reason 4 O O
vaccines Reason 4 O O
offer Reason 4 O O
advantages Reason 4 O O
over Reason 4 O O
currently Reason 4 O O
available Reason 4 O O
COVID-19 Reason 4 O O
vaccines. Reason 4 O O
Main Reason 4 O O
As Reason 4 O O
of Reason 4 O O
2023, Reason 4 O O
13 Reason 4 O O
COVID-19 Reason 4 O O
vaccines Reason 4 O O
have Reason 4 O O
met Reason 4 O O
the Reason 4 O O
standards Reason 4 O O
for Reason 4 O O
emergency Reason 4 O O
use Reason 4 O O
listing Reason 4 O O
(EUL) Reason 4 O O
by Reason 4 O O
the Reason 4 O O
WHO Reason 4 ScientificAuthority O
[1](/articles/s41564-023-01352-8#ref-CR1). Reason 4 O O
Authorized Reason 4 O O
vaccines Reason 4 O O
include Reason 4 O O
inactivated Reason 4 O O
virus Reason 4 O O
subunit Reason 4 O O
vaccines, Reason 4 O O
adenoviral-vectored Reason 4 O O
spike Reason 4 O O
and Reason 4 O O
nucleoside-modified Reason 4 O O
mRNA Reason 4 O O
vaccines Reason 4 O O
[2](/articles/s41564-023-01352-8#ref-CR2). O O O O
While Reason 5 O O
available Reason 5 O O
vaccines Reason 5 O O
provide Reason 5 O O
long-lasting Reason 5 O O
protection Reason 5 O O
from Reason 5 O O
severe Reason 5 O O
illness, Reason 5 O O
waning Reason 5 O O
of Reason 5 O O
immunity Reason 5 O O
is Reason 5 O O
evident, Reason 5 O O
particularly Reason 5 O O
following Reason 5 O O
the Reason 5 O O
emergence Reason 5 O O
and Reason 5 O O
spread Reason 5 O O
of Reason 5 O O
omicron Reason 5 O O
variants Reason 5 O O
[3](/articles/s41564-023-01352-8#ref-CR3), Reason 5 O O
[4](/articles/s41564-023-01352-8#ref-CR4). Reason 5 O O
Optimal Reason 5 O O
COVID-19 Reason 5 O O
vaccines Reason 5 O O
protect Reason 5 O O
from Reason 5 O O
severe Reason 5 O O
disease, Reason 5 O O
span Reason 5 O O
a Reason 5 O O
broad Reason 5 O O
spectrum Reason 5 O O
of Reason 5 O O
virus Reason 5 O O
variants Reason 5 O O
and Reason 5 O O
prevent Reason 5 O O
or Reason 5 O O
limit Reason 5 O O
SARS-CoV-2 Reason 5 O O
transmission. Reason 5 O O
Live-attenuated Reason 5 O O
vaccines Reason 5 O O
(LAV), Reason 5 O O
which Reason 5 O O
have Reason 5 O O
been Reason 5 O O
successfully Reason 5 O O
used Reason 5 O O
against Reason 5 O O
virus Reason 5 O O
infections Reason 5 O O
such Reason 5 O O
as Reason 5 O O
measles, Reason 5 O O
mumps Reason 5 O O
and Reason 5 O O
rubella Reason 5 O O
(MMR) Reason 5 O O
[5](/articles/s41564-023-01352-8#ref-CR5), Reason 5 O O
offer Reason 5 O O
advantages Reason 5 O O
over Reason 5 O O
other Reason 5 O O
types Reason 5 O O
of Reason 5 O O
vaccines. Reason 5 O O
They O O O O
do O O O O
not O O O O
require O O O O
adjuvants O O O O
[6](/articles/s41564-023-01352-8#ref-CR6) O O O O
and O O O O
can O O O O
be O O O O
administered O O O O
locally, O O O O
for O O O O
example O O O O
intranasally, O O O O
as O O O O
in O O O O
the O O O O
case O O O O
of O O O O
influenza O O O O
LAVs O O O O
[7](/articles/s41564-023-01352-8#ref-CR7). O O O O
Composed O O O O
of O O O O
replication-competent O O O O
viruses, O O O O
intranasal O O O O
LAVs O O O O
mimic O O O O
the O O O O
natural O O O O
course O O O O
of O O O O
infection O O O O
and O O O O
antigen O O O O
production, O O O O
which O O O O
distinguishes O O O O
them O O O O
from O O O O
locally O O O O
administered, O O O O
replication-incompetent O O O O
vector- O O O O
or O O O O
antigen-based O O O O
vaccines O O O O
[8](/articles/s41564-023-01352-8#ref-CR8). O O O O
In O O O O
contrast O O O O
to O O O O
empirically O O O O
generated O O O O
vaccines O O O O
used O O O O
in O O O O
the O O O O
past, O O O O
modern O O O O
LAV O O O O
design O O O O
utilizes O O O O
molecular O O O O
tools O O O O
to O O O O
limit O O O O
virus O O O O
replication O O O O
and O O O O
virulence O O O O
while O O O O
maintaining O O O O
immunogenicity O O O O
and O O O O
antigenic O O O O
integrity O O O O
[9](/articles/s41564-023-01352-8#ref-CR9). O O O O
One O O O O
recent O O O O
strategy O O O O
employed O O O O
in O O O O
the O O O O
rational O O O O
design O O O O
of O O O O
LAVs O O O O
is O O O O
codon O O O O
pair O O O O
deoptimization O O O O
(CPD), O O O O
which O O O O
is O O O O
suitable O O O O
for O O O O
both O O O O
DNA O O O O
[10](/articles/s41564-023-01352-8#ref-CR10) O O O O
and O O O O
RNA O O O O
viruses O O O O
[11](/articles/s41564-023-01352-8#ref-CR11), O O O O
including O O O O
SARS-CoV-2 O O O O
[12](/articles/s41564-023-01352-8#ref-CR12). O O O O
Current Reason 5 O O
COVID-19 Reason 5 O O
vaccines Reason 5 O O
are Reason 5 O O
administered Reason 5 O O
intramuscularly Reason 5 O O
and Reason 5 O O
efficiently Reason 5 O O
induce Reason 5 O O
systemic Reason 5 O O
immunity, Reason 5 O O
including Reason 5 O O
high Reason 5 O O
titre Reason 5 O O
of Reason 5 O O
neutralizing Reason 5 O O
antibodies, Reason 5 O O
central Reason 5 O O
and Reason 5 O O
effector Reason 5 O O
memory Reason 5 O O
T Reason 5 O O
cells Reason 5 O O
[13](/articles/s41564-023-01352-8#ref-CR13), O O O O
nasal-resident O O O O
CD8+ O O O O
T O O O O
cells O O O O
[14](/articles/s41564-023-01352-8#ref-CR14), O O O O
centre O O O O
B O O O O
cells O O O O
[15](/articles/s41564-023-01352-8#ref-CR15) O O O O
and O O O O
long-lived O O O O
plasma O O O O
cells O O O O
[16](/articles/s41564-023-01352-8#ref-CR16). O O O O
However, O O O O
this O O O O
route O O O O
is O O O O
less O O O O
effective O O O O
in O O O O
inducing O O O O
durable O O O O
mucosal O O O O
IgA O O O O
and O O O O
IgG O O O O
responses O O O O
[17](/articles/s41564-023-01352-8#ref-CR17), O O O O
[18](/articles/s41564-023-01352-8#ref-CR18) O O O O
and O O O O
pulmonary O O O O
tissue-resident O O O O
memory O O O O
cell O O O O
responses O O O O
[19](/articles/s41564-023-01352-8#ref-CR19). O O O O
Mucosal O O O O
antibodies O O O O
at O O O O
the O O O O
site O O O O
of O O O O
virus O O O O
entry O O O O
play O O O O
crucial O O O O
roles O O O O
in O O O O
limiting O O O O
infectivity O O O O
and O O O O
transmission O O O O
[20](/articles/s41564-023-01352-8#ref-CR20). O O O O
Accordingly, O O O O
tissue-resident O O O O
memory O O O O
cells O O O O
undergo O O O O
faster O O O O
recall O O O O
responses O O O O
due O O O O
to O O O O
local O O O O
positioning O O O O
and O O O O
allow O O O O
earlier O O O O
cognate O O O O
antigen O O O O
recognition O O O O
[21](/articles/s41564-023-01352-8#ref-CR21). O O O O
Hence, Reason 4 O O
vaccines Reason 4 O O
administered Reason 4 O O
via Reason 4 O O
respiratory Reason 4 O O
routes Reason 4 O O
are Reason 4 O O
expected Reason 4 O O
to Reason 4 O O
provide Reason 4 O O
robust Reason 4 O O
local Reason 4 O O
mucosal Reason 4 O O
immunity Reason 4 O O
against Reason 4 O O
targeted Reason 4 O O
pathogens Reason 4 O O
[22](/articles/s41564-023-01352-8#ref-CR22). O O O O
Here Reason 5 O O
we Reason 5 O O
compare Reason 5 O O
different Reason 5 O O
vaccines Reason 5 O O
and Reason 5 O O
vaccine Reason 5 O O
regimens, Reason 5 O O
evaluating Reason 5 O O
systemic Reason 5 O O
and Reason 5 O O
mucosal Reason 5 O O
immunity Reason 5 O O
conferred Reason 5 O O
by Reason 5 O O
each Reason 5 O O
vaccine. Reason 5 O O
Results Reason 5 O O
In Reason 5 O O
a Reason 5 O O
heterologous Reason 5 O O
SARS-CoV-2 Reason 5 O O
Delta Reason 5 O O
challenge Reason 5 O O
setting, Reason 5 O O
we Reason 5 O O
evaluated Reason 5 O O
efficacy Reason 5 O O
and Reason 5 O O
mode Reason 5 O O
of Reason 5 O O
action Reason 5 O O
of Reason 5 O O
the Reason 5 O O
commercial Reason 5 O O
mRNA Reason 5 O O
vaccine Reason 5 O O
BNT162b2 Reason 5 O O
and Reason 5 O O
two Reason 5 O O
vaccine Reason 5 O O
candidates, Reason 5 O O
Ad2-Spike, Reason 5 O O
an Reason 5 O O
adenoviral Reason 5 O O
vector Reason 5 O O
carrying Reason 5 O O
spike Reason 5 O O
[25](/articles/s41564-023-01352-8#ref-CR25). Reason 5 O O
To Reason 5 O O
assess Reason 5 O O
efficacy, Reason 5 O O
Syrian Reason 5 O O
hamsters Reason 5 O O
were Reason 5 O O
vaccinated Reason 5 O O
with Reason 5 O O
a Reason 5 O O
single Reason 5 O O
dose Reason 5 O O
(prime-only Reason 5 O O
regimen) Reason 5 O O
and Reason 5 O O
challenged Reason 5 O O
with Reason 5 O O
SARS-CoV-2 Reason 5 O O
Delta Reason 5 O O
variant Reason 5 O O
21 Reason 5 O O
d Reason 5 O O
post Reason 5 O O
vaccination. Reason 5 O O
Another Reason 5 O O
group Reason 5 O O
of Reason 5 O O
hamsters Reason 5 O O
received Reason 5 O O
two Reason 5 O O
vaccine Reason 5 O O
doses Reason 5 O O
21 Reason 5 O O
d Reason 5 O O
apart Reason 5 O O
(prime-boost Reason 5 O O
regimen) Reason 5 O O
and Reason 5 O O
were Reason 5 O O
challenge-infected Reason 5 O O
14 Reason 5 O O
d Reason 5 O O
after Reason 5 O O
boosting Reason 5 O O
(Fig. Reason 5 O O
[1a](/articles/s41564-023-01352-8#Fig1)). Reason 5 O O
All Reason 5 O O
vaccinations Reason 5 O O
were Reason 5 O O
well Reason 5 O O
tolerated, Reason 5 O O
as Reason 5 O O
evidenced Reason 5 O O
by Reason 5 O O
steady Reason 5 O O
weight Reason 5 O O
gains Reason 5 O O
post Reason 5 O O
vaccination Reason 5 O O
(Extended Reason 5 O O
Data Reason 5 O O
Fig. Reason 5 O O
[1a](/articles/s41564-023-01352-8#Fig7)). Reason 5 O O
Vaccination Reason 5 O O
alleviates Reason 5 O O
clinical Reason 5 O O
symptoms Reason 5 O O
and Reason 5 O O
reduces Reason 5 O O
virus Reason 5 O O
load Reason 5 O O
All Reason 5 O O
vaccination Reason 5 O O
strategies Reason 5 O O
protected Reason 5 O O
hamsters Reason 5 O O
from Reason 5 O O
SARS-CoV-2 Reason 5 O O
infection-induced Reason 5 O O
body Reason 5 O O
weight Reason 5 O O
loss Reason 5 O O
(Fig. Reason 5 O O
[1b](/articles/s41564-023-01352-8#Fig1)). Reason 5 O O
Following Reason 4 O O
a Reason 4 O O
single Reason 4 O O
vaccination, Reason 4 O O
none Reason 4 O O
of Reason 4 O O
the Reason 4 O O
vaccines Reason 4 O O
completely Reason 4 O O
prevented Reason 4 O O
infection Reason 4 O O
by Reason 4 O O
SARS-CoV-2 Reason 4 O O
Delta Reason 4 O O
as Reason 4 O O
evidenced Reason 4 O O
by Reason 4 O O
the Reason 4 O O
presence Reason 4 O O
of Reason 4 O O
viral Reason 4 O O
RNA Reason 4 O O
in Reason 4 O O
respiratory Reason 4 O O
tracts Reason 4 O O
(Fig. Reason 4 O O
[1c,d](/articles/s41564-023-01352-8#Fig1)). Reason 4 O O
Only Reason 4 O O
sCPD9 Reason 4 O O
vaccine Reason 4 O O
effectively Reason 4 O O
reduced Reason 4 O O
replicating Reason 4 O O
virus Reason 4 O O
to Reason 4 O O
undetectable Reason 4 O O
levels Reason 4 O O
2 Reason 4 O O
d Reason 4 O O
post Reason 4 O O
challenge Reason 4 O O
(dpc) Reason 4 O O
(Fig. Reason 4 O O
[1e](/articles/s41564-023-01352-8#Fig1)). Reason 4 O O
Prime-boost Reason 5 O O
vaccination Reason 5 O O
improved Reason 5 O O
overall Reason 5 O O
vaccine Reason 5 O O
efficacy Reason 5 O O
against Reason 5 O O
SARS-CoV-2 Reason 5 O O
(Fig. Reason 5 O O
[1f,g](/articles/s41564-023-01352-8#Fig1)). Reason 5 O O
Following Reason 5 O O
prime-boost Reason 5 O O
vaccination, Reason 5 O O
viral Reason 5 O O
RNA Reason 5 O O
was Reason 5 O O
significantly Reason 5 O O
reduced, Reason 5 O O
yet Reason 5 O O
still Reason 5 O O
detectable Reason 5 O O
in Reason 5 O O
all Reason 5 O O
groups Reason 5 O O
in Reason 5 O O
oropharyngeal Reason 5 O O
swabs Reason 5 O O
and Reason 5 O O
lungs. Reason 5 O O
Vaccination Reason 5 O O
schemes Reason 5 O O
using Reason 5 O O
sCPD9 Reason 5 O O
were Reason 5 O O
superior Reason 5 O O
in Reason 5 O O
reducing Reason 5 O O
viral Reason 5 O O
RNA Reason 5 O O
(Fig. Reason 5 O O
[1f,g](/articles/s41564-023-01352-8#Fig1)). Reason 5 O O
Similarly, Reason 5 O O
levels Reason 5 O O
of Reason 5 O O
replication-competent Reason 5 O O
virus Reason 5 O O
in Reason 5 O O
lungs Reason 5 O O
were Reason 5 O O
significantly Reason 5 O O
reduced Reason 5 O O
in Reason 5 O O
vaccinated Reason 5 O O
animals Reason 5 O O
at Reason 5 O O
2 Reason 5 O O
dpc. Reason 5 O O
Importantly, Reason 5 O O
only Reason 5 O O
sCPD9 Reason 5 O O
booster Reason 5 O O
vaccination Reason 5 O O
reduced Reason 5 O O
replicating Reason 5 O O
virus Reason 5 O O
levels Reason 5 O O
below Reason 5 O O
the Reason 5 O O
detection Reason 5 O O
threshold, Reason 5 O O
regardless Reason 5 O O
of Reason 5 O O
heterologous Reason 5 O O
(mRNA) Reason 5 O O
or Reason 5 O O
homologous Reason 5 O O
(sCPD9) Reason 5 O O
priming Reason 5 O O
(Fig. Reason 5 O O
[1h](/articles/s41564-023-01352-8#Fig1)). Reason 5 O O
Results Reason 5 O O
were Reason 5 O O
confirmed Reason 5 O O
by Reason 5 O O
sequencing Reason 5 O O
of Reason 5 O O
bulk Reason 5 O O
RNA Reason 5 O O
from Reason 5 O O
lungs Reason 5 O O
(Extended Reason 5 O O
Data Reason 5 O O
Fig. Reason 5 O O
[1b](/articles/s41564-023-01352-8#Fig7)). Reason 5 O O
LAV O O O O
is O O O O
superior O O O O
in O O O O
preventing O O O O
inflammatory O O O O
lung O O O O
damage O O O O
To O O O O
determine O O O O
infection-induced O O O O
lung O O O O
damage, O O O O
challenged O O O O
hamsters O O O O
were O O O O
examined O O O O
by O O O O
histopathology. O O O O
After Reason 4 O O
single Reason 4 O O
vaccination, Reason 4 O O
sCPD9 Reason 4 O O
was Reason 4 O O
most Reason 4 O O
efficient Reason 4 O O
in Reason 4 O O
preventing Reason 4 O O
inflammation Reason 4 O O
and Reason 4 O O
pneumonia, Reason 4 O O
as Reason 4 O O
evidenced Reason 4 O O
by Reason 4 O O
lesser Reason 4 O O
consolidated Reason 4 O O
lung Reason 4 O O
areas Reason 4 O O
(Fig. Reason 4 O O
[1m](/articles/s41564-023-01352-8#Fig1)) Reason 4 O O
and Reason 4 O O
lower Reason 4 O O
scores Reason 4 O O
for Reason 4 O O
lung Reason 4 O O
inflammation, Reason 4 O O
bronchitis Reason 4 O O
and Reason 4 O O
oedema Reason 4 O O
(Fig. Reason 4 O O
[1i,j](/articles/s41564-023-01352-8#Fig1) Reason 4 O O
and Reason 4 O O
Extended Reason 4 O O
Data Reason 4 O O
Fig. Reason 4 O O
[1c-f](/articles/s41564-023-01352-8#Fig7)). Reason 4 O O
Notably, Reason 2 O O
animals Reason 2 O O
that Reason 2 O O
received Reason 2 O O
other Reason 2 O O
vaccination Reason 2 O O
schedules Reason 2 O O
displayed Reason 2 O O
more Reason 2 O O
prominent Reason 2 O O
bronchial Reason 2 O O
hyperplasia Reason 2 O O
(Extended Reason 2 O O
Data Reason 2 O O
Fig. Reason 2 O O
[2](/articles/s41564-023-01352-8#Fig8)). Reason 2 O O
A O O O O
similar O O O O
trend O O O O
was O O O O
observed O O O O
for O O O O
prime-boost O O O O
regimens; O O O O
however, O O O O
particularly O O O O
the O O O O
mRNA O O O O
vaccine O O O O
displayed O O O O
an O O O O
improved O O O O
histological O O O O
outcome O O O O
resulting O O O O
from O O O O
homologous O O O O
boost O O O O
(Fig. O O O O
[1k,l](/articles/s41564-023-01352-8#Fig1) O O O O
and O O O O
Extended O O O O
Data O O O O
Fig. O O O O
[1g-j](/articles/s41564-023-01352-8#Fig7)). O O O O
Overall, Reason 5 O O
homologous Reason 5 O O
sCPD9 Reason 5 O O
prime-boost Reason 5 O O
vaccination Reason 5 O O
provided Reason 5 O O
superior Reason 5 O O
lung Reason 5 O O
protection Reason 5 O O
from Reason 5 O O
inflammation Reason 5 O O
(Figs. O O O O
[1m](/articles/s41564-023-01352-8#Fig1) O O O O
and O O O O
[2a](/articles/s41564-023-01352-8#Fig2), O O O O
and O O O O
Extended O O O O
Data O O O O
Fig. O O O O
[2](/articles/s41564-023-01352-8#Fig8)). O O O O
Lung Reason 4 O O
transcriptome Reason 4 O O
analysis Reason 4 O O
also Reason 4 O O
showed Reason 4 O O
a Reason 4 O O
broad Reason 4 O O
downregulation Reason 4 O O
of Reason 4 O O
infection- Reason 4 O O
and Reason 4 O O
inflammation-related Reason 4 O O
genes Reason 4 O O
in Reason 4 O O
vaccinated Reason 4 O O
hamsters, Reason 4 O O
with Reason 4 O O
the Reason 4 O O
greatest Reason 4 O O
effects Reason 4 O O
seen Reason 4 O O
in Reason 4 O O
homologous Reason 4 O O
and Reason 4 O O
heterologous Reason 4 O O
sCDP9 Reason 4 O O
vaccinations Reason 4 O O
(Supplementary O O O O
Fig. O O O O
[1](/articles/s41564-023-01352-8#MOESM1)). O O O O
To O O O O
correlate O O O O
levels O O O O
of O O O O
inflammation O O O O
with O O O O
cellular O O O O
responses, O O O O
we O O O O
performed O O O O
single-cell O O O O
RNA O O O O
sequencing O O O O
(scRNA-seq) O O O O
of O O O O
lung O O O O
samples O O O O
(Fig. O O O O
[2b](/articles/s41564-023-01352-8#Fig2) O O O O
and O O O O
Supplementary O O O O
Fig. O O O O
[2a](/articles/s41564-023-01352-8#MOESM1)). O O O O
Results Reason 4 O O
showed Reason 4 O O
that Reason 4 O O
pulmonary Reason 4 O O
recruitment Reason 4 O O
of Reason 4 O O
monocytic Reason 4 O O
macrophages Reason 4 O O
was Reason 4 O O
significantly Reason 4 O O
reduced Reason 4 O O
in Reason 4 O O
sCPD9 Reason 4 O O
+ Reason 4 O O
sCPD9-vaccinated Reason 4 O O
animals Reason 4 O O
at Reason 4 O O
2 Reason 4 O O
dpc Reason 4 O O
(Fig. O O O O
[2c](/articles/s41564-023-01352-8#Fig2) O O O O
and O O O O
Supplementary O O O O
Fig O O O O
